NCT07389473 Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
| NCT ID | NCT07389473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gaize |
| Condition | ADHD |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-04-17 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-04-17 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.
Eligibility Criteria
Inclusion Criteria: * Adults aged between 18 and 65, having given written informed consent to participate in the research trial. * Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months. * Normal or corrected to normal vision using either glasses or contact lenses, or surgery. Exclusion Criteria: * Enrolled in, or participated in another clinical trial within 30 days before the study * Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days. * Had your eyes dilated by a medical doctor in the previous 24 hours. * Photosensitive epilepsy * Diagnosed with clinical blindness * Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded. * Current or past head inject/ traumatic brain injury (TBI) * Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications. * History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well. * Potential participants who are unable to provide consent for the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07389473 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying ADHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07389473 currently recruiting?
Yes, NCT07389473 is actively recruiting participants. Contact the research team at apurva.raje@gaize.ai for enrollment information.
Where is the NCT07389473 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07389473 clinical trial?
NCT07389473 is sponsored by Gaize. The trial plans to enroll 50 participants.